BioCryst Pharmaceuticals, Inc. Free Cash Flow

Free Cash Flow of BCRX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow growth rates and interactive chart. Free cash flowis calculated as operating cash flow minus of capital expenditures. Interest payments are excluded from the generally accepted definition of free cash flow. Free cash flow is the cash flow available to all the investors in a company, including common stockholders, preferred shareholders, and lenders. Some investors prefer FCF or FCF per share over earnings and earnings per share as a measure of profitability. However, because FCF accounts for investments in property, plant, and equipment it can be lumpy over time. Free cash flow is usually used in discounted cash flow models to determine a company's intrinsic value.

Highlights and Quick Summary

  • Free Cash Flow for the quarter ending September 30, 2022 was $-32.6 Million (a 16.49% increase compared to previous quarter)
  • Year-over-year quarterly Free Cash Flow decreased by -2.82%
  • Annual Free Cash Flow for 2021 was $-145 Million (a 6.58% increase from previous year)
  • Annual Free Cash Flow for 2020 was $-136 Million (a 50.81% increase from previous year)
  • Annual Free Cash Flow for 2019 was $-89.9 Million (a -3.23% decrease from previous year)
  • Twelve month Free Cash Flow ending September 30, 2022 was $-172 Million (a 5.49% increase compared to previous quarter)
  • Twelve month trailing Free Cash Flow increased by 19.27% year-over-year
Trailing Free Cash Flow for the last four month:
30 Sep '22 30 Jun '22 31 Mar '22 31 Dec '21
$-172 Million $-163 Million $-162 Million $-145 Million
Visit stockrow.com/BCRX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow of BioCryst Pharmaceuticals, Inc.

Most recent Free Cash Flowof BCRX including historical data for past 10 years.

Interactive Chart of Free Cash Flow of BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. Free Cash Flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 – $-32.62 $-28.0 $-78.21 –
2021 $-33.57 $-23.64 $-26.22 $-61.11 $-144.54
2020 $-42.69 $-38.43 $-31.11 $-23.4 $-135.62
2019 $-10.53 $-27.72 $-24.59 $-27.09 $-89.93
2018 $-24.09 $-35.07 $-14.08 $-19.69 $-92.93
2017 $-10.62 $-12.62 $-9.69 $-8.53 $-41.46
2016 $-5.85 $-17.74 $-13.02 $-22.1 $-58.71
2015 $-18.87 $-12.8 $17.73 $-4.29 $-18.24
2014 $-13.96 $-8.63 $-7.1 $-8.97 $-38.66
2013 $-4.52 $-7.87 $-2.92 $-11.2 $-26.51
2012 $-7.03 $-11.78 $-6.38 $-12.32 $-37.51

Business Profile of BioCryst Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
© stockrow.com